Headquartered in Jupiter, FL Fiscal year ends December NASDAQ: LGND ligand.com
Ligand Pharmaceuticals is a biopharmaceutical royalty aggregator. It finances and advances partners' late-stage clinical programs in exchange for long-term economic interests such as royalties and milestones.
Following its July 2026 acquisition of XOMA Royalty, its portfolio more than doubled to over 200 commercial, clinical and preclinical royalty assets. Key royalty assets include:
- Travere's Filspari
- Merck's Ohtuvayre and Capvaxive
- Roche's Vabysmo
- Servier/Ipsen's Ojemda
- Zevra's Miplyffa
- Santen's Ryjunea
- Pelthos' Zelsuvmi
Its development-stage assets include Takeda's mezagitamab, Mirum's volixibat, Palvella's Qtorin rapamycin and Orchestra BioMed's AVIM Therapy.
Royalties make up the large majority of revenue. Ligand also sells and licenses its Captisol drug formulation technology and licenses its NITRICIL platform, and earns contract revenue from partners. It funds investments through cash, short-term investments, convertible senior notes and a credit facility. Updated
Wall Street analysts are making bold moves on Tuesday, shaking up ratings for some of the biggest names in tech, biotech, and retail in ways that could catch investors off guard. Find…
The S&P 500 is up 10.3% YTD, and Wall Street is convinced the markets have more room to run, particularly for this group of stocks we have uncovered. JPMorgan just tagged CECO Environmental…
Pre-Market Stock Futures: Futures are trading lower as we hit the mid-point of the trading week, and while we didn’t see the snapback rally that was the star of the show Monday,…
Here is a look at how shares of FuelCell Energy, Gilead Sciences, Starbucks and more have fared since their initial public offerings in 1992.
Tuesday's top analyst upgrades and downgrades included Array Technologies, CarMax, Caterpillar, Cleveland-Cliffs, Eaton, First Solar, Intercontinental Exchange, Medical Properties Trust, Paramount Global and Tesla.
Short sellers seem to have many emerging and speculative biotech stocks targeted for termination. Here are eight of them against which short sellers are betting the farm.
In a new research report, RBC did some intense digging in the small-cap arena and came up with some fascinating research. These are five top small-cap growth plays suited for aggressive accounts.
Lee Jackson The top analyst upgrades, downgrades and initiations seen on Wednesday included Activision Blizzard, Biogen, Deere, DocuSign, Ford, Freeport-McMoRan, General Motors, Lattice Semiconductor, Qualys, Shopify and Under Armour.
Nordstrom, Tailored Brands, Electronics for Imaging and Ligand Pharmaceuticals had all posted new 52-week lows by noon Wednesday.
The top analyst upgrades, downgrades and other research calls from Monday included Amazon.com, Anheuser-Busch Inbev, Caterpillar, HUYA, Ligand Pharmaceuticals, Verizon and Weyerhaeuser.
The top analyst upgrades, downgrades and other research calls from Friday include DSW, Dean Foods, Fluor, JD.com, Nvidia, Viper Energy and Walmart.
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include Barrick Gold, Caterpillar, ConocoPhillips, PNC Financial, Tonix Pharmaceuticals and Spirit Realty.
Insider selling is likely to keep ramping higher, as many on Wall Street see volatility going higher this summer as we get closer to the political cycle home stretch.
We mentioned often that the market has not seen a 10% correction for three years. This week's selling may very well get that talking point off the books and set the stage…
Monday's top analyst upgrades, downgrades and initiations include EMC, Herbalife, Micron Technology, Petrobras and SanDisk.
Ligand Pharmaceuticals is a biopharmaceutical royalty aggregator. It finances and advances partners' late-stage clinical programs in exchange for long-term economic interests such as royalties and milestones.
The Wall Street consensus 12-month price target for LGND is $360.82.
